FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792333450> ?p ?o ?g. }

• W2792333450 endingPage "iii8" @default.
• W2792333450 startingPage "iii8" @default.
• W2792333450 abstract "Background: AVID100, an anti-EGFR-DM1 conjugate, showed potent activity in preclinical models in vitro and in vivo including in cell lines resistant to approved anti-EGFR mAbs. Methods: Patients with advanced or metastatic epithelial malignancies without available therapy and likely to express EGFR are being enrolled into sequential dose escalation cohorts (Phase 1a) to assess safety, tolerability, and PK parameters to identify the recommended Phase 2 dose (R2PD) of 1-hour infusions on an every 3 week schedule. In the Phase 2a segment preliminary antitumor activity will be assessed in expansion cohorts of patients with breast cancer (BC) and squamous cell carcinoma of the head and neck (SCCHN) with EGFR overexpression (3+ in ≥ 50% of tumor cells). Results: No cycle 1 dose limiting toxicities (DLTs) have been observed in Cohorts 1-6 (dose (N); 20 (1), 40 (1), 80 (3), 120 (3), 180 (3), and 220 (3) mg/m2 every 3 weeks). Currently, patients are being evaluated in Cohort 7 (270 mg/m2; approximately 6.9 mg/kg). Preliminary clinical PK results show exposure levels of AVID100 have been achieved that exceed therapeutic levels predicted from preclinical studies. Safety and tolerability have been acceptable with G2-3 lipase elevations without clinical sequelae, infusion-related reactions ameliorated by premedication and infusion prolongation, reversible thrombocytopenia, and reversible transaminase elevations without other evidence of hepatic toxicity. Other G1-2 treatment-related adverse events reported include: rash, nausea, vomiting, fatigue, headache, anorexia, mucositis, diarrhea, elevated amylase, elevated alkaline phosphatase, hypomagnesemia, and hypokalemia. Patients entered to the Phase 1a segment were not screened for EGFR overexpression and included patients with: colorectal cancer (9); breast cancer (2); and single cases of ovarian, pancreatic, urothelial, and cervical cancer. Prolonged disease stabilization has been observed in 3 of these unselected patients (colorectal, ovarian, cervical). Conclusions: AVID100 is a well-tolerated anti-EGFR-DM1 conjugate with evidence for exposure levels at or above those observed for cetuximab and ado-trastuzumab emtansine. Antitumor activity will be evaluated in EGFR-overexpressing patients with BC and SCCHN. Clinical trial identification: NCT03094169 Legal entity responsible for the study: Formation Biologics Funding: CPRIT Disclosure: A. Tolcher: Former investigator for Formation Biologics and am currently a member of the Board of Directors of Formation Biologics. K. Papadopoulos: Investigator on a clinical study for Formation Biologics. Y. Cole, K. Rivas: Research nurse working on a clinical study for Formation Biologics. S. Chandana, N. Lakhani: Investigator on a study for Formation Biologics. S. Sinclair: Employee of Formation Biologics. D. Wood, P.I. Nadler: Medical consultant for Formation Biologics." @default.
• W2792333450 created "2018-03-29" @default.
• W2792333450 creator A5001736304 @default.
• W2792333450 creator A5003770647 @default.
• W2792333450 creator A5036708021 @default.
• W2792333450 creator A5058606655 @default.
• W2792333450 creator A5059997105 @default.
• W2792333450 creator A5060992997 @default.
• W2792333450 creator A5066473113 @default.
• W2792333450 creator A5071409429 @default.
• W2792333450 creator A5079014717 @default.
• W2792333450 date "2018-03-01" @default.
• W2792333450 modified "2023-09-25" @default.
• W2792333450 title "A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate" @default.
• W2792333450 doi "https://doi.org/10.1093/annonc/mdy048.004" @default.
• W2792333450 hasPublicationYear "2018" @default.
• W2792333450 type Work @default.
• W2792333450 sameAs 2792333450 @default.
• W2792333450 citedByCount "3" @default.
• W2792333450 countsByYear W27923334502018 @default.
• W2792333450 countsByYear W27923334502020 @default.
• W2792333450 countsByYear W27923334502023 @default.
• W2792333450 crossrefType "journal-article" @default.
• W2792333450 hasAuthorship W2792333450A5001736304 @default.
• W2792333450 hasAuthorship W2792333450A5003770647 @default.
• W2792333450 hasAuthorship W2792333450A5036708021 @default.
• W2792333450 hasAuthorship W2792333450A5058606655 @default.
• W2792333450 hasAuthorship W2792333450A5059997105 @default.
• W2792333450 hasAuthorship W2792333450A5060992997 @default.
• W2792333450 hasAuthorship W2792333450A5066473113 @default.
• W2792333450 hasAuthorship W2792333450A5071409429 @default.
• W2792333450 hasAuthorship W2792333450A5079014717 @default.
• W2792333450 hasBestOaLocation W27923334501 @default.
• W2792333450 hasConcept C126322002 @default.
• W2792333450 hasConcept C143998085 @default.
• W2792333450 hasConcept C197934379 @default.
• W2792333450 hasConcept C2777063308 @default.
• W2792333450 hasConcept C2778375690 @default.
• W2792333450 hasConcept C2778496288 @default.
• W2792333450 hasConcept C2778570526 @default.
• W2792333450 hasConcept C2780580376 @default.
• W2792333450 hasConcept C29730261 @default.
• W2792333450 hasConcept C71924100 @default.
• W2792333450 hasConcept C90924648 @default.
• W2792333450 hasConcept C98274493 @default.
• W2792333450 hasConceptScore W2792333450C126322002 @default.
• W2792333450 hasConceptScore W2792333450C143998085 @default.
• W2792333450 hasConceptScore W2792333450C197934379 @default.
• W2792333450 hasConceptScore W2792333450C2777063308 @default.
• W2792333450 hasConceptScore W2792333450C2778375690 @default.
• W2792333450 hasConceptScore W2792333450C2778496288 @default.
• W2792333450 hasConceptScore W2792333450C2778570526 @default.
• W2792333450 hasConceptScore W2792333450C2780580376 @default.
• W2792333450 hasConceptScore W2792333450C29730261 @default.
• W2792333450 hasConceptScore W2792333450C71924100 @default.
• W2792333450 hasConceptScore W2792333450C90924648 @default.
• W2792333450 hasConceptScore W2792333450C98274493 @default.
• W2792333450 hasLocation W27923334501 @default.
• W2792333450 hasOpenAccess W2792333450 @default.
• W2792333450 hasPrimaryLocation W27923334501 @default.
• W2792333450 hasRelatedWork W1541193958 @default.
• W2792333450 hasRelatedWork W1973342136 @default.
• W2792333450 hasRelatedWork W2002502340 @default.
• W2792333450 hasRelatedWork W2022556905 @default.
• W2792333450 hasRelatedWork W2243375749 @default.
• W2792333450 hasRelatedWork W2393784267 @default.
• W2792333450 hasRelatedWork W2394317912 @default.
• W2792333450 hasRelatedWork W2896565415 @default.
• W2792333450 hasRelatedWork W4251165208 @default.
• W2792333450 hasRelatedWork W2183331092 @default.
• W2792333450 hasVolume "29" @default.
• W2792333450 isParatext "false" @default.
• W2792333450 isRetracted "false" @default.
• W2792333450 magId "2792333450" @default.
• W2792333450 workType "article" @default.